Through rigorous assessment and prioritization, Bayer is advancing key programs with significant potential. (Image Credits: Pixabay) Bayer on Tuesday announced that it was preparing market ...

Investors looking for a quick turnaround in the fortunes of Bayer are likely to be disappointed by chief executive Bill Anderson's assessment of the next couple of years as he delivers the group's ...

In a statement, Bayer said that after reviewing the data for eliapixant (formerly BAY1817080 ) it had concluded that "the overall benefit no long outweighs the risk" in the drug's four target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...